Minimal residual disease prognostic value for relapse-free survival of children with acute lymphoblastic leukemia treating according to ALL-MB-2002 protocol (monofactorial and multifactirial analysis)
https://doi.org/10.17650/1818-8346-2009-0-2-17-21
Abstract
220 children with acute lymphoblastic leukemia (ALL) treated according to ALL-MB-2002 protocol are included in the study. Minimal residual disease (MRD) estimated in bone marrow by three-color flow cytometry on day 15 (n=99), day 36 (n=107) and before the maintenance therapy (n=60). Day 36 positive MRD level (≥0.01%) as one of unfavorable factors statistically significant worsening of relapse-free survival was revealed (log-rank test; р<0.05). In multifactorial analysis (Cox regression) it is revealed that positive MRD level on day 36 of treatment is the strongest and independent prognostic factor influencing relapse probability (hazard ratio 6.6; p=0.031). Necessity of additional patients' stratification introduction according to MRD level after induction is proved.
About the Authors
N. N. Savva
Republic Centre for Paediatric Oncology and Haematology
Belarus
Belarus
Minsk
O. V. Kras'ko
Republic Centre for Paediatric Oncology and Haematology
Belarus
Belarus
Minsk
M. V. Belevtcev
Republic Centre for Paediatric Oncology and Haematology
Belarus
Belarus
Minsk
V. P. Savitckiy
Republic Centre for Paediatric Oncology and Haematology
Belarus
Belarus
Minsk
N. V. Migal
Republic Centre for Paediatric Oncology and Haematology
Belarus
Belarus
Minsk
O. V. Aleinikova
Republic Centre for Paediatric Oncology and Haematology
Belarus
Belarus
Minsk
References
1. Савва Н.Н., Зборовская А.А., Алейникова О.В. Злокачественные новообразования у детей Республики Беларусь: заболеваемость, выживаемость, смертность, паллиативная помощь. Минск: РНМБ, 2008.
2. Campana D., Pui C. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995;85:1416—34.
3. Coustan-Smith E., Sancho J., Hancock M.L. et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;96:2691—6.
4. Campana D. Monitoring minimal residual disease in acute leukemia: expectations, possibilities and initial clinical results. Int J Clin Lab Res 1994;24:1—7.
5. International BFM Study Group (IBFM-SG). Minimal residual diseasedirected risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008;22(4):771—82.
6. Children's Oncology Group. Clinical significance of MRD in childhood ALL and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008;111(12):5477—85.
7. Mussolin L., Pillon M., Conter V. et al. Prognostic role of minimal residual disease in mature B-cell ALL of childhood. J Clin Oncol 2007;25(33):5254—61.
8. Fronkova E., Mejstrikova E., Avigad S. et al. Minimal residual disease (MRD) analysis in the non-MRD-based ALL ICBFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia 2008;22(5):989—97.
9. Szczepa_ski T. Why and how to quantify minimal residual disease in ALL? Leukemia 2007;21(4):622—6.
10. Dvorgak M.N., Panzer-Grumaer E.R. Flow cytometric detection of minimal residual disease in acute lymphoblastic leukemia. Leuk Lymohoma 2003;44:1445—55.
11. Karachunskiy A., Herold R., von Stackelberg A. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia. Leukemia 2008;22(6):1144—53.
12. Белевцев М.В., Савицкий В.П., Савва Н.Н. и др. Определение остаточных опухолевых клеток в костном мозге детей с В-линейным острым лимфобластным лейкозом методом проточной цитофлюориметрии. Клин лабор диагност 2006;10:42–5.
13. Davies S., Borowitz M., Rosner G. Pharmacogenetics of minimal residual disease response in children with B-precursor ALL: a report from the Children's Oncology Group. Blood 2008;111(6):2984—90.
14. Van der Velden V. MRD levels in BM and PB are comparable in children with T cell ALL, but not in precursor-B-ALL. Leukemia 2002;16(8):1432—6.
15. Sramkova L., Muzikova K., Fronkova E. et al. Detectable MRD before alloHSCT predicts extremely poor prognosis in children with ALL. Pediatr Blood Cancer 2007;8(1):93—100.
16. Schilham M., Balduzzi A., Bader P. PD-WP of the EBMT. Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells? Bone Marrow Transplant 2005;35(Suppl 1):49—52.
17. Kwok C., Kham S., Ariffin H. et al. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwiniaasparaginase in childhood acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer 2006;47(3):299—304.
18. Andersson A., Ritz C., Lindgren D. et al. Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia 2007;21(6):1198—203.
Review
For citations:
Savva N.N., Kras'ko O.V., Belevtcev M.V., Savitckiy V.P., Migal N.V., Aleinikova O.V. Minimal residual disease prognostic value for relapse-free survival of children with acute lymphoblastic leukemia treating according to ALL-MB-2002 protocol (monofactorial and multifactirial analysis). Oncohematology. 2009;(2):17-21. (In Russ.) https://doi.org/10.17650/1818-8346-2009-0-2-17-21
Views:
214
Email this article 